Tuesday, October 6, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 2, 2026

Agora, Inc. Reports Fourth Quarter and Fiscal Year 2025 Financial Results

View original at globenewswire.com
Agora, Inc. Reports Fourth Quarter and Fiscal Year 2025 Financial Results SANTA CLARA, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Agora, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Company expects Q1 2026 total revenues between $36 million and $37 million, representing 8.1% to 11.1% year-over-year growth

    80% confidence

  • Company achieved fifth consecutive quarter of GAAP profitability, marking first full year of profitability since 2018, driven by sustained double-digit revenue growth

    80% confidence

  • Platform's scalability was validated during Super Bowl live shopping event with nearly 600,000 peak concurrent viewers and sub-second latency

    80% confidence

  • Company started 2026 with strong reception of conversational AI solutions for Physical AI at CES, highlighted by leading vision and motion control capabilities

    80% confidence

  • Company remains focused on driving revenue growth and advancing conversational AI innovation throughout 2026

    80% confidence

  • Conversational AI engine usage has more than doubled each quarter since March 2025 launch

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com